John Kanzius battled leukemia and invented a cancer-fighting machine during his struggle with the disease. He died before his idea for curing cancer could be fully tested. His physician, Dr Steven Curley, has been trying to see if Kansius' dream can become a reality. Kanzius' invention may hold the promise of treating people who are stricken by the disease each year.

Instead of the classic scalpel, surgeons can also operate with an electroscalpel. A significant advantage to this technique is that while a cut is being made, blood vessels are closed off and hemorrhaging eliminated. Now another advantage may be added as well: a German-Hungarian research team has developed a mass-spectrometry-based technique by which tissues can be analyzed during a surgical procedure.

UC Irvine researchers have created a new approach that vastly improves the targeting of chemotherapeutic drugs to specific cells and organs.

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

Huachansu, a Chinese medicine that comes from the dried venom secreted by the skin glands of toads, has tolerable toxicity levels, even at doses eight times those normally administered, and may slow disease progression in some cancer patients, say researchers from The University of Texas M. D. Anderson Cancer Center.

A group of scientists from Hamburg may have taken a big step towards more effective cancer drug development, Europe's largest cancer congress, ECCO 15 – ESMO 34 [1], heard today (Wednesday 23 September). Dr Ilona Schonn, Director of Cell Culture Research at Indivumed GmbH, told the conference that they had developed a preclinical drug test platform that would enable researchers to analyse tumour tissue for individual patient drug responses on the molecular level.

A new study just released by the researchers from the University of Utah and Columbia University shows there is a link to the virus XMRV to prostate cancer. The study results were published in the Proceedings of the National Academy of Sciences showed that 27% of the human prostate cancer tumors in the study had XMRV.

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Université de Montréal, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

The teaming up of Direget and the Karmanos Cancer Institute raises hopes for brighter futures for cancer research.

Here's a pressing story about how patient's receive cancer treatment might change - and very soon. Medicare is proposing cuts that would affect Americans undergoing cancer treatment and limit their options. The decision for this is happening on Monday, August 31.